Viral T-cell epitopes - Identification, characterization and clinical application

Semin Immunol. 2023 Mar:66:101725. doi: 10.1016/j.smim.2023.101725. Epub 2023 Jan 25.

Abstract

T-cell immunity, mediated by CD4+ and CD8+ T cells, represents a cornerstone in the control of viral infections. Virus-derived T-cell epitopes are represented by human leukocyte antigen (HLA)-presented viral peptides on the surface of virus-infected cells. They are the prerequisite for the recognition of infected cells by T cells. Knowledge of viral T-cell epitopes provides on the one hand a diagnostic tool to decipher protective T-cell immune responses in the human population and on the other hand various prophylactic and therapeutic options including vaccination approaches and the transfer of virus-specific T cells. Such approaches have already been proven to be effective against various viral infections, particularly in immunocompromised patients lacking sufficient humoral, antibody-based immune response. This review provides an overview on the state of the art as well as current studies regarding the identification and characterization of viral T-cell epitopes and approaches of clinical application. In the first chapter in silico prediction tools and direct, mass spectrometry-based identification of viral T-cell epitopes is compared. The second chapter provides an overview of commonly used assays for further characterization of T-cell responses and phenotypes. The final chapter presents an overview of clinical application of viral T-cell epitopes with a focus on human immunodeficiency virus (HIV), human cytomegalovirus (HCMV) and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), being representatives of relevant viruses.

Keywords: DC vaccination; Immunopeptidomics; In silico prediction; Mass spectrometry; Peptide vaccination; T-cell assays; T-cell epitope characterization; T-cell epitopes; T-cell transfer; Viral infection.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes*
  • COVID-19*
  • Epitopes, T-Lymphocyte
  • Histocompatibility Antigens Class I
  • Humans
  • SARS-CoV-2

Substances

  • Epitopes, T-Lymphocyte
  • Histocompatibility Antigens Class I